The project will develop new compounds against three therapeutic targets linked to tumor inflammation and will study their combined use to improve immunotherapies. The initiative has been funding with more than 2.5 million euros and is part of a Retos Colaboración call.
The Molecular Pharmacology and Experimental Therapeutics (MPET) research group, led by Marçal Pastor-Anglada, director of IBUB, is one of the world leaders in the study of the transporters of adenosine, a crucial nucleoside in the regulation of the tumor microenvironment. In this project, they will develop new compounds against some of the pathways by which tumor cells evade the action of the immune system and immunotherapy. This innovative research will evaluate the potential synergy between these compounds, which will be used to treat most solid tumors, especially those in advanced stages and resistant to current treatments.
The consortium is led by Palobiofarma, the first Spanish company to submit an immunotherapy against cancer to clinical trials and, in addition to the IBUB (UB-FGB), it has the participation of Medibiofarma, the University of Santiago de Compostela and the Hospital de la Santa Creu i Sant Pau.